There are 2949 resources available
1300P - Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial
Presenter: Sanjay Popat
Session: E-Poster Display
Resources:
Abstract
1301P - Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses
Presenter: Shirish Gadgeel
Session: E-Poster Display
Resources:
Abstract
1302P - Lorlatinib in patients with ALK+ NSCLC treated beyond initial disease progression
Presenter: Sai.Ignatious Ou
Session: E-Poster Display
Resources:
Abstract
1303P - Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Presenter: Simon Baldacci
Session: E-Poster Display
Resources:
Abstract
1304P - Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L
Presenter: Myung-Ju Ahn
Session: E-Poster Display
Resources:
Abstract
1305P - Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L
Presenter: Maria Rosario Garcia Campelo
Session: E-Poster Display
Resources:
Abstract
1306P - Platin pemetrexed with or without bevacizumab with upfront versus “at progression” brain radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis: A randomized phase III trial (Metal2 trial)
Presenter: Isabelle Monnet
Session: E-Poster Display
Resources:
Abstract
1307P - Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD)
Presenter: Rafal Dziadziuszko
Session: E-Poster Display
Resources:
Abstract
1308P - Effect of current treatment evolution in advanced NSCLC on overall survival in the real world
Presenter: Aria Shokoohi
Session: E-Poster Display
Resources:
Abstract
1309P - ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)
Presenter: Alexander Spira
Session: E-Poster Display
Resources:
Abstract